1
|
Schutter JD, Eberhardt K, Elert AM, Radnik J, Geißler D, Ozcan O. Synthesis and characterization of lipopolysaccharide (LPS) anchored polystyrene microparticles as a synthetic model system for attachment studies. Colloids Surf B Biointerfaces 2023; 226:113301. [PMID: 37075524 DOI: 10.1016/j.colsurfb.2023.113301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2022] [Revised: 03/04/2023] [Accepted: 04/05/2023] [Indexed: 04/21/2023]
Abstract
Outer membrane lipopolysaccharides (LPS) play a crucial role in determining attachment behavior and pathogenicity of bacteria. The aim of this study was to develop a simple procedure for anchoring bacterial lipopolysaccharides to polystyrene (PS) microparticles as a model system for in situ attachment studies. By using a swell-capture methodology, commercially available LPS of Pseudomonas aeruginosa (strain ATCC 27316 serotype 10.22) was anchored onto PS microparticles in a proof-of-concept study. A detailed chemical and morphological characterization has proven the success of LPS incorporation. It was shown that the coverage and structure of the LPS film was concentration dependent. The procedure can easily be adapted to LPS of other bacterial strains to generate a synthetic model toolkit for attachment studies.
Collapse
Affiliation(s)
- Jan David Schutter
- Bundesanstalt für Materialforschung und -prüfung (BAM), Unter den Eichen 87, 12205 Berlin, Germany
| | - Karl Eberhardt
- Bundesanstalt für Materialforschung und -prüfung (BAM), Unter den Eichen 87, 12205 Berlin, Germany
| | - Anna Maria Elert
- Bundesanstalt für Materialforschung und -prüfung (BAM), Unter den Eichen 87, 12205 Berlin, Germany
| | - Jörg Radnik
- Bundesanstalt für Materialforschung und -prüfung (BAM), Unter den Eichen 87, 12205 Berlin, Germany
| | - Daniel Geißler
- Bundesanstalt für Materialforschung und -prüfung (BAM), Unter den Eichen 87, 12205 Berlin, Germany; PolyAn GmbH, Schkopauer Ring 6, 12681 Berlin, Germany
| | - Ozlem Ozcan
- Bundesanstalt für Materialforschung und -prüfung (BAM), Unter den Eichen 87, 12205 Berlin, Germany.
| |
Collapse
|
2
|
Shende P, Gupta S. Role of lipopolysaccharides in potential applications of nanocarrier systems. Curr Pharm Des 2021; 28:1000-1010. [PMID: 34818999 DOI: 10.2174/1381612827666211124094302] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2021] [Accepted: 08/24/2021] [Indexed: 11/22/2022]
Abstract
BACKGROUND Lipopolysaccharides (LPS) are considered the main molecular component in the outer membrane of gram-negative bacteria. The LPS molecule in the bacterial cell wall acts as a primary physical barrier and protects gram-negative bacteria from the surrounding environment. LPS (endotoxins) show immunomodulatory therapeutic properties as well as toxicity to the host cell, whereas potential applications encompass. OBJECTIVE This review article aims to describe the recent developments of lipopolysaccharides in nanocarrier systems for various applications such as vaccination, cancer chemotherapy and immune stimulants action. Different nanocarriers like cubosomes, niosomes, dendrimers and metal nanoparticles used in the delivery of actives are employed to decorate lipopolysaccharide molecules superficially. METHODS A narrative review of all the relevant papers known to the author was conducted. CONCLUSION Commercially available lipid nanoparticles contribute to many advances as promising nanocarriers in cancer therapy and are used as a vaccine adjuvant by improving the immune response due to their properties such as size, shape, biocompatibility, and biodegradability. Whereas lipopolysaccharide-decorated nanoparticles change the host's tolerability and increase the effectiveness of molecule in cancer immunotherapy. These nanoconjugate systems enhance overall immunogenic response and effectiveness in vaccine immunotherapy and targeted therapy, not only limited to humans application but also for poultry and aquaculture. Newer opportunities using lipopolysaccharides for the treatment and management of diseases with unique characteristics like the presence of lipoprotein that act as an alternative for bacterial infections over conventional dosage forms.
Collapse
Affiliation(s)
- Pravin Shende
- Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM'S NMIMS, V. L. Mehta Road, Vile Parle (W), Mumbai. India
| | - Shubham Gupta
- Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM'S NMIMS, V. L. Mehta Road, Vile Parle (W), Mumbai. India
| |
Collapse
|
3
|
Sadeghi M, Keshavarz Shahbaz S, Dehnavi S, Koushki K, Sankian M. Current possibilities and future perspectives for improving efficacy of allergen-specific sublingual immunotherapy. Int Immunopharmacol 2021; 101:108350. [PMID: 34782275 DOI: 10.1016/j.intimp.2021.108350] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2021] [Revised: 11/02/2021] [Accepted: 11/04/2021] [Indexed: 10/19/2022]
Abstract
Allergen-specific sublingual immunotherapy (SLIT), a safe and efficient route for treating type I hypersensitivity disorders, requires high doses of allergens. SLIT is generally performed without adjuvants and delivery systems. Therefore, allergen formulation with appropriate presentation platforms results in improved allergen availability, targeting the immune cells, inducing regulatory immune responses, and enhancing immunotherapy's efficacy while decreasing the dose of the allergen. In this review, we discuss the adjuvants and delivery systems that have been applied as allergen-presentation platforms for SLIT. These adjuvants include TLRs ligands, 1α, 25-dihydroxy vitamin D3, galectin-9, probiotic and bacterial components that provoke allergen-specific helper type-1 T lymphocytes (TH1), and regulatory T cells (Tregs). Another approach is encapsulation or adsorption of the allergens into a particulate vector system to facilitate allergen capture by tolerogenic dendritic cells. Also, we proposed strategies to increasing the efficacy of SLIT via new immunopotentiators and carrier systems in the future.
Collapse
Affiliation(s)
- Mahvash Sadeghi
- Department of Immunology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
| | - Sanaz Keshavarz Shahbaz
- Cellular and Molecular Research Center, Research Institute for Prevention of Non-communicable Disease, Qazvin University of Medical Sciences, Qazvin, Iran
| | - Sajad Dehnavi
- Department of Immunology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
| | - Khadijeh Koushki
- Hepatitis Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran
| | - Mojtaba Sankian
- Immunobiochemistry Lab, Immunology Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
| |
Collapse
|
4
|
Di Gioacchino M, Petrarca C, Gatta A, Scarano G, Farinelli A, Della Valle L, Lumaca A, Del Biondo P, Paganelli R, Di Giampaolo L. Nanoparticle-based immunotherapy: state of the art and future perspectives. Expert Rev Clin Immunol 2020; 16:513-525. [PMID: 32343153 DOI: 10.1080/1744666x.2020.1762572] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
INTRODUCTION For several years now, medicine has been benefiting from the contribution of nanoparticles (NPs) technology for both diagnosis and therapy. They can be used as adjuvants, being capable per se of immune-modulating activity, or as carriers for molecules to be transported to a specific target, eventually loaded with specific ligands favoring specific uptake. AREAS COVERED The review focuses on experimental use of NPs as adjuvants/carriers for allergen immunotherapy (AIT). Human clinical trials conducted so far are discussed. EXPERT OPINION Results of experimental studies and recent clinical trials support the use of NPs as carrier/adjuvant in AIT. Comparisons between NP-based and classical AIT are needed, to show the usefulness of the NP-based approach. However, there are still unsolved problems: the persistence of non-degradable NPs with possible toxicological consequences, and the formation of the protein corona around the NPs, which could alter their activity and fate. Virus-like particles seem the most promising NPs for allergy treatment, as for other vaccines. Over the next decade, NP-based AIT will be largely used to treat allergic disorders.
Collapse
Affiliation(s)
- Mario Di Gioacchino
- Department of Medicine and Science of Ageing, G. d'Annunzio University , Chieti, Pescara, Italy.,Leonardo Da Vinci, University , Chieti, Italy.,Department of Medicine and Science of Ageing, Specialization School of Allergy and Clinical Immunology, G. d'Annunzio University Chieti-Pescara , Italy
| | - Claudia Petrarca
- Department of Medicine and Science of Ageing, G. d'Annunzio University , Chieti, Pescara, Italy
| | - Alessia Gatta
- Department of Medicine and Science of Ageing, G. d'Annunzio University , Chieti, Pescara, Italy
| | - Gilda Scarano
- Department of Medicine and Science of Ageing, G. d'Annunzio University , Chieti, Pescara, Italy.,Department of Medicine and Science of Ageing, Specialization School of Allergy and Clinical Immunology, G. d'Annunzio University Chieti-Pescara , Italy
| | - Anila Farinelli
- Department of Medicine and Science of Ageing, G. d'Annunzio University , Chieti, Pescara, Italy.,Department of Medicine and Science of Ageing, Specialization School of Allergy and Clinical Immunology, G. d'Annunzio University Chieti-Pescara , Italy
| | - Loredana Della Valle
- Department of Medicine and Science of Ageing, G. d'Annunzio University , Chieti, Pescara, Italy.,Department of Medicine and Science of Ageing, Specialization School of Allergy and Clinical Immunology, G. d'Annunzio University Chieti-Pescara , Italy
| | - Arianna Lumaca
- Department of Medicine and Science of Ageing, G. d'Annunzio University , Chieti, Pescara, Italy.,Department of Medicine and Science of Ageing, Specialization School of Allergy and Clinical Immunology, G. d'Annunzio University Chieti-Pescara , Italy
| | - Pietro Del Biondo
- Department of Medicine and Science of Ageing, G. d'Annunzio University , Chieti, Pescara, Italy.,Department of Medicine and Science of Ageing, Specialization School of Allergy and Clinical Immunology, G. d'Annunzio University Chieti-Pescara , Italy
| | - Roberto Paganelli
- Department of Medicine and Science of Ageing, G. d'Annunzio University , Chieti, Pescara, Italy.,Department of Medicine and Science of Ageing, Specialization School of Allergy and Clinical Immunology, G. d'Annunzio University Chieti-Pescara , Italy
| | - Luca Di Giampaolo
- Department of Medical Oral and Biotechnological Sciences, G. d'Annunzio University , Chieti, Pescara, Italy
| |
Collapse
|
5
|
Cui X, Bao L, Wang X, Chen C. The Nano-Intestine Interaction: Understanding the Location-Oriented Effects of Engineered Nanomaterials in the Intestine. SMALL (WEINHEIM AN DER BERGSTRASSE, GERMANY) 2020; 16:e1907665. [PMID: 32347646 DOI: 10.1002/smll.201907665] [Citation(s) in RCA: 31] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/30/2019] [Revised: 02/13/2020] [Accepted: 02/18/2020] [Indexed: 06/11/2023]
Abstract
Engineered nanomaterials (ENMs) are used in food additives, food packages, and therapeutic purposes owing to their useful properties, Therefore, human beings are orally exposed to exogenous nanomaterials frequently, which means the intestine is one of the primary targets of nanomaterials. Consequently, it is of great importance to understand the interaction between nanomaterials and the intestine. When nanomaterials enter into gut lumen, they inevitably interact with various components and thereby display different effects on the intestine based on their locations; these are known as location-oriented effects (LOE). The intestinal LOE confer a new biological-effect profile for nanomaterials, which is dependent on the involvement of the following biological processes: nano-mucus interaction, nano-intestinal epithelial cells (IECs) interaction, nano-immune interaction, and nano-microbiota interaction. A deep understanding of NM-induced LOE will facilitate the design of safer NMs and the development of more efficient nanomedicine for intestine-related diseases. Herein, recent progress in this field is reviewed in order to better understand the LOE of nanomaterials. The distant effects of nanomaterials coupling with microbiota are also highlighted. Investigation of the interaction of nanomaterials with the intestine will stimulate other new research areas beyond intestinal nanotoxicity.
Collapse
Affiliation(s)
- Xuejing Cui
- CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety & CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, 100190, China
| | - Lin Bao
- CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety & CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, 100190, China
- University of Chinese Academy of Sciences, Beijing, 100049, China
| | - Xiaoyu Wang
- CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety & CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, 100190, China
- University of Chinese Academy of Sciences, Beijing, 100049, China
| | - Chunying Chen
- CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety & CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, 100190, China
- GBA Research Innovation Institute for Nanotechnology, Guangdong, 510700, China
| |
Collapse
|
6
|
Shetab Boushehri MA, Abdel-Mottaleb MMA, Béduneau A, Pellequer Y, Lamprecht A. A nanoparticle-based approach to improve the outcome of cancer active immunotherapy with lipopolysaccharides. Drug Deliv 2018; 25:1414-1425. [PMID: 29902933 PMCID: PMC6058527 DOI: 10.1080/10717544.2018.1469684] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
Abstract
This study sought to develop a simple nanoparticle-based approach to enhance the efficiency and tolerability of lipopolysaccharide (LPS), a potent ligand of Toll-like Receptor 4 (TLR4), for immunotherapy in cancer. Despite holding promise within this context, the strong pro-inflammatory properties of LPS also account for its low tolerability given localized and systemic side effects, which restrict the administrable dosage. Herein, we investigated the effect of LPS decoration as a surface-active molecule on a polymeric matrix upon its efficiency and tolerability. The LPS-decorated nanoparticles (LPS-NP) were about 150 nm in size, with slightly negative zeta potential (about -15 mV) and acceptable LPS incorporation (about 70%). In vitro, the particles accounted for a higher induction of apoptosis in tumor cells cultured with murine splenocytes compared to LPS solution. When used for the treatment of a murine syngeneic colorectal tumor model, higher intratumoral deposition of the particle-bound LPS was observed. Furthermore, unlike LPS solution, which accounted for localized necrosis at high concentrations, treatment of tumor-bearing animals with equivalent doses of LPS-NP was well tolerated. We propose that the observed localized necrosis can be Shwartzman phenomenon, which, due to modulated 24-h post-injection systemic TNF-α and LPS concentrations, have been avoided in case of LPS-NP. This has in turn enhanced the therapeutic efficiency and enabled complete tumor regression at concentrations at which LPS solution was intolerable. The findings indicate that nanoparticles can serve as beyond carriers for the delivery of superficially decorated LPS molecules, but impact their overall efficiency and tolerability in cancer therapy.
Collapse
Affiliation(s)
| | - Mona M A Abdel-Mottaleb
- a Department of Pharmaceutics , University of Bonn , Bonn , Germany.,b Laboratory of Pharmaceutical Engineering (EA4267) , University of Franche-Comté , Besançon , France.,c Department of Pharmaceutics and Industrial Pharmacy , Faculty of Pharmacy, Ain Shams University , Cairo , Egypt
| | - Arnaud Béduneau
- b Laboratory of Pharmaceutical Engineering (EA4267) , University of Franche-Comté , Besançon , France
| | - Yann Pellequer
- b Laboratory of Pharmaceutical Engineering (EA4267) , University of Franche-Comté , Besançon , France
| | - Alf Lamprecht
- a Department of Pharmaceutics , University of Bonn , Bonn , Germany.,b Laboratory of Pharmaceutical Engineering (EA4267) , University of Franche-Comté , Besançon , France
| |
Collapse
|
7
|
Gamazo C, D'Amelio C, Gastaminza G, Ferrer M, Irache JM. Adjuvants for allergy immunotherapeutics. Hum Vaccin Immunother 2018; 13:2416-2427. [PMID: 28825867 DOI: 10.1080/21645515.2017.1348447] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Allergic diseases are reaching epidemic proportions in developed countries. In particular, food allergy is increasing in prevalence and severity, thus becoming an important socioeconomic burden. Numerous cell types and cell populations, which form an intricate and balanced network, are involved in an immune response. This balance is occasionally disturbed, leading to the onset of different diseases, such as allergic diseases. Antihistamines and corticosteroids provide some degree of relief from the symptoms of allergic conditions. However, the only treatment that can revert the disease is immunotherapy. Nevertheless, specific immunotherapy has at least 2 major drawbacks: it is time-consuming, and it can produce local and even systemic allergic side effects. Immunotherapy's potential goes beyond our current knowledge of the immune response; nevertheless, we can still design strategies to reach a safer immune modulation for treating allergies. This review deals with the use of adjuvants to reduce the undesirable side effects associated with specific allergen immunotherapy. For example, nanoparticles used as immunoadjuvants are offering promising results in preclinical assays.
Collapse
Affiliation(s)
- Carlos Gamazo
- a Dept. Microbiology , Instituto de Investigación Sanitaria de Navarra (Idisna), University of Navarra , Pamplona , Spain
| | - Carmen D'Amelio
- b Department of Allergology and Clinical Immunology , Clínica Universidad de Navarra-Pamplona , Pamplona , Spain
| | - Gabriel Gastaminza
- c Department of Allergology and Clinical Immunology , Clínica Universidad de Navarra-Pamplona , Pamplona , Spain
| | - Marta Ferrer
- d Department of Allergology and Clinical Immunology , Clínica Universidad de Navarra-Pamplona , Pamplona , Spain
| | - Juan M Irache
- e Dept. Pharmacy and Pharmaceutical Technology , University of Navarra , Pamplona , Spain
| |
Collapse
|
8
|
Brotons-Canto A, Gamazo C, Martín-Arbella N, Abdulkarim M, Matías J, Gumbleton M, Irache JM. Evaluation of nanoparticles as oral vehicles for immunotherapy against experimental peanut allergy. Int J Biol Macromol 2018; 110:328-335. [DOI: 10.1016/j.ijbiomac.2017.09.109] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2017] [Accepted: 09/27/2017] [Indexed: 01/07/2023]
|
9
|
Pohlit H, Bellinghausen I, Frey H, Saloga J. Recent advances in the use of nanoparticles for allergen-specific immunotherapy. Allergy 2017; 72:1461-1474. [PMID: 28474379 DOI: 10.1111/all.13199] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/29/2017] [Indexed: 12/28/2022]
Abstract
The number of patients suffering from allergic asthma and rhinoconjunctivitis has increased dramatically within the last decades. Allergen-specific immunotherapy (AIT) is the only available cause-oriented therapy so far. AIT reduces symptoms, but has also a disease-modifying effect. Disadvantages are a long-lasting procedure, and in a few cases potential systemic adverse reactions. Encapsulation of allergens or DNA vaccines into nanostructures may provide advantages compared to the conventional AIT with noncapsulated allergen extracts: The protein/DNA molecule can be protected from degradation, higher local concentrations and targeted delivery to the site of action appear possible, and most importantly, recognition of encapsulated allergen by the immune system, especially by IgE antibodies, is prevented. AIT with nanoparticles (NPs) may offer a safer and potentially more efficient way of treatment for allergic diseases. In this review, we summarize the use of biodegradable NPs consisting of synthetic or natural polymers, liposomes, and virus-like particles as well as nonbiodegradable NPs like dendrimers, and carbon- or metal-based NPs for AIT. More or less successful applications of these NPs in prophylactic as well as therapeutic vaccination approaches in rodents or other animals as well as first human clinical trials are discussed in detail.
Collapse
Affiliation(s)
- H. Pohlit
- Department of Dermatology; University Medical Center of the Johannes Gutenberg University Mainz; Mainz Germany
- Institute of Organic Chemistry; Johannes Gutenberg-University Mainz; Mainz Germany
- Graduate School of Excellence Materials Science in Mainz; Johannes Gutenberg-University Mainz; Mainz Germany
| | - I. Bellinghausen
- Department of Dermatology; University Medical Center of the Johannes Gutenberg University Mainz; Mainz Germany
| | - H. Frey
- Institute of Organic Chemistry; Johannes Gutenberg-University Mainz; Mainz Germany
| | - J. Saloga
- Department of Dermatology; University Medical Center of the Johannes Gutenberg University Mainz; Mainz Germany
| |
Collapse
|
10
|
Brotons-Canto A, Martín-Arbella N, Gamazo C, Irache JM. New pharmaceutical approaches for the treatment of food allergies. Expert Opin Drug Deliv 2016; 15:675-686. [PMID: 27732129 DOI: 10.1080/17425247.2016.1247805] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
INTRODUCTION Allergic diseases constitute one of the most common causes of chronic illness in developed countries. The main mechanism determining allergy is an imbalance between Th1 and Th2 response towards Th2. AREAS COVERED This review describes the mechanisms underlying the natural tolerance to food components and the development of an allergic response in sensitized individuals. Furthermore, therapeutic approaches proposed to manage these abnormal immunologic responses food are also presented and discussed. EXPERT OPINION In the past, management of food allergies has consisted of the education of patients to avoid the ingestion of the culprit food and to initiate the therapy (e.g. self-injectable epinephrine) in case of accidental ingestion. In recent years, sublingual/oral immunotherapies based on the continuous administration of small amounts of the allergen have been developed. However, the long periods of time needed to obtain significant desensitization and the generation of adverse effects, limit their use. In order to solve these drawbacks, strategies to induce tolerance are being studied, such as the use of either adjuvant immunotherapy in order to facilitate the reversion of the Th2 response towards Th1 or the use of monoclonal antibodies to block the main immunogenic elements.
Collapse
Affiliation(s)
- Ana Brotons-Canto
- a Department of Pharmacy and Pharmaceutical Technology , University of Navarra , Pamplona , Spain
| | - Nekane Martín-Arbella
- a Department of Pharmacy and Pharmaceutical Technology , University of Navarra , Pamplona , Spain
| | - Carlos Gamazo
- b Department of Microbiology , University of Navarra , Pamplona , Spain
| | - Juan M Irache
- a Department of Pharmacy and Pharmaceutical Technology , University of Navarra , Pamplona , Spain
| |
Collapse
|
11
|
Scheiblhofer S, Machado Y, Feinle A, Thalhamer J, Hüsing N, Weiss R. Potential of nanoparticles for allergen-specific immunotherapy - use of silica nanoparticles as vaccination platform. Expert Opin Drug Deliv 2016; 13:1777-1788. [PMID: 27321476 DOI: 10.1080/17425247.2016.1203898] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
INTRODUCTION Allergen-specific immunotherapy is the only curative approach for the treatment of allergies. There is an urgent need for improved therapies, which increase both, efficacy and patient compliance. Novel routes of immunization and the use of more advanced vaccine platforms have gained heightened interest in this field. Areas covered: The current status of allergen-specific immunotherapy is summarized and novel routes of immunization and their challenges in the clinics are critically discussed. The use of nanoparticles as novel delivery system for allergy vaccines is comprehensively reviewed. Specifically, the advantages of silica nanoparticles as vaccine carriers and adjuvants are summarized. Expert opinion: Future allergen-specific immunotherapy will combine engineered hypoallergenic vaccines with novel routes of administration, such as the skin. Due to their biodegradability, and the easiness to introduce surface modifications, silica nanoparticles are promising candidates for tailor-made vaccines. By covalently linking allergens and polysaccharides to silica nanoparticles, a versatile vaccination platform can be designed to specifically target antigen-presenting cells, render the formulation hypoallergenic, and introduce immunomodulatory functions. Combining potent skin vaccination methods, such as fractional laser ablation, with nanoparticle-based vaccines addresses all the requirements for safe and efficient therapy of allergic diseases.
Collapse
Affiliation(s)
- Sandra Scheiblhofer
- a Department of Molecular Biology, Division of Allergy and Immunology , University of Salzburg , Salzburg , Austria
| | - Yoan Machado
- a Department of Molecular Biology, Division of Allergy and Immunology , University of Salzburg , Salzburg , Austria
| | - Andrea Feinle
- b Department of Chemistry and Physics of Materials, Materials Chemistry Division , University of Salzburg , Salzburg , Austria
| | - Josef Thalhamer
- a Department of Molecular Biology, Division of Allergy and Immunology , University of Salzburg , Salzburg , Austria
| | - Nicola Hüsing
- b Department of Chemistry and Physics of Materials, Materials Chemistry Division , University of Salzburg , Salzburg , Austria
| | - Richard Weiss
- a Department of Molecular Biology, Division of Allergy and Immunology , University of Salzburg , Salzburg , Austria
| |
Collapse
|
12
|
Wen R, Umeano AC, Francis L, Sharma N, Tundup S, Dhar S. Mitochondrion: A Promising Target for Nanoparticle-Based Vaccine Delivery Systems. Vaccines (Basel) 2016; 4:E18. [PMID: 27258316 PMCID: PMC4931635 DOI: 10.3390/vaccines4020018] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2016] [Revised: 03/31/2016] [Accepted: 04/08/2016] [Indexed: 02/07/2023] Open
Abstract
Vaccination is one of the most popular technologies in disease prevention and eradication. It is promising to improve immunization efficiency by using vectors and/or adjuvant delivery systems. Nanoparticle (NP)-based delivery systems have attracted increasing interest due to enhancement of antigen uptake via prevention of vaccine degradation in the biological environment and the intrinsic immune-stimulatory properties of the materials. Mitochondria play paramount roles in cell life and death and are promising targets for vaccine delivery systems to effectively induce immune responses. In this review, we focus on NPs-based delivery systems with surfaces that can be manipulated by using mitochondria targeting moieties for intervention in health and disease.
Collapse
Affiliation(s)
- Ru Wen
- NanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602, USA.
| | - Afoma C Umeano
- NanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602, USA.
| | - Lily Francis
- NanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602, USA.
| | - Nivita Sharma
- NanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602, USA.
| | - Smanla Tundup
- School of Medicine, Department of Pulmonary and Critical Care, University of Virginia, Charlottesville, WV 22908, USA.
| | - Shanta Dhar
- NanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602, USA.
| |
Collapse
|
13
|
Dobrovolskaia MA, Shurin M, Shvedova AA. Current understanding of interactions between nanoparticles and the immune system. Toxicol Appl Pharmacol 2016; 299:78-89. [PMID: 26739622 PMCID: PMC4811709 DOI: 10.1016/j.taap.2015.12.022] [Citation(s) in RCA: 193] [Impact Index Per Article: 24.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2015] [Revised: 12/24/2015] [Accepted: 12/26/2015] [Indexed: 10/22/2022]
Abstract
The delivery of drugs, antigens, and imaging agents benefits from using nanotechnology-based carriers. The successful translation of nanoformulations to the clinic involves thorough assessment of their safety profiles, which, among other end-points, includes evaluation of immunotoxicity. The past decade of research focusing on nanoparticle interaction with the immune system has been fruitful in terms of understanding the basics of nanoparticle immunocompatibility, developing a bioanalytical infrastructure to screen for nanoparticle-mediated immune reactions, beginning to uncover the mechanisms of nanoparticle immunotoxicity, and utilizing current knowledge about the structure-activity relationship between nanoparticles' physicochemical properties and their effects on the immune system to guide safe drug delivery. In the present review, we focus on the most prominent pieces of the nanoparticle-immune system puzzle and discuss the achievements, disappointments, and lessons learned over the past 15years of research on the immunotoxicity of engineered nanomaterials.
Collapse
Affiliation(s)
- Marina A Dobrovolskaia
- Nanotechnology Characterization Laboratory, Cancer Research Technology Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, NCI at Frederick, Frederick, MD 21702, USA.
| | - Michael Shurin
- Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA; Department of Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
| | - Anna A Shvedova
- Health Effects Laboratory Division, National Institute of Occupational Safety and Health, Centers for Disease Control and Prevention, Morgantown, WV 26505, USA; Department of Physiology and Pharmacology, West Virginia University, Morgantown, WV 26506, USA.
| |
Collapse
|
14
|
Marć MA, Domínguez-Álvarez E, Gamazo C. Nucleic acid vaccination strategies against infectious diseases. Expert Opin Drug Deliv 2015; 12:1851-65. [PMID: 26365499 DOI: 10.1517/17425247.2015.1077559] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
INTRODUCTION Gene vaccines are an interesting and emerging alternative for the prevention of infectious diseases, as well as in the treatment of other pathologies including cancer, allergies, autoimmune diseases, or even drug dependencies. When applied to the target organism, these vaccines induce the expression of encoded antigens and elicit the corresponding immune response, with the potential ability of being able to induce antibody-, helper T cell-, and cytotoxic T cell-mediated immune responses. AREAS COVERED Special attention is paid to the variety of adjuvants that may be co-administered to enhance and/or to modulate immune responses, and to the methods of delivery. Finally, this article reviews the efficacy data of gene vaccines against infectious diseases released from current clinical trials. EXPERT OPINION Taken together, this approach will have a major impact on future strategies for the prevention of infectious diseases. Better-designed nucleic acid constructs, novel delivery technologies, as well as the clarification of the mechanisms for antigen presentation will improve the potential applications of this vaccination strategy against microbial pathogens.
Collapse
Affiliation(s)
- Małgorzata Anna Marć
- a 1 Jagiellonian University Medical College, Faculty of Pharmacy, Department of Pharmaceutical Biochemistry , Medyczna 9, PL 30-688 Cracow, Poland
| | - Enrique Domínguez-Álvarez
- b 2 Jagiellonian University Medical College, Faculty of Pharmacy, Department of Technology and Biotechnology of Drugs , Medyczna 9, PL 30-688 Cracow, Poland
| | - Carlos Gamazo
- c 3 University of Navarra, Institute of Tropical Health (ISTUN), Department of Microbiology and Parasitology , Irunlarrea 1, 31008 Pamplona, Spain
| |
Collapse
|
15
|
Gamazo C, Gastaminza G, Ferrer M, Sanz ML, Irache JM. Nanoparticle based-immunotherapy against allergy. Immunotherapy 2014; 6:885-97. [DOI: 10.2217/imt.14.63] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Allergic diseases are one of the most prevalent diseases, reaching epidemic proportions in developed countries. An allergic reaction occurs after contact with an environmental protein, such as inhalants allergens (pollen, animal dander, house dust mites), or food proteins. This response is known as part of the type 2 immunity that is counterbalanced by Type 1 immunity and Tregs. Widely used allergen-specific immunotherapy (IT) is a long term treatment to induce such switch from Th2 to Th1 response. However, conventional IT requires multiple allergen injections over a long period of time and is not free of risk of producing allergic reactions. As a consequence, new safer and faster immunotherapeutic methods are required. This review deals with allergen IT using nanoparticles as allergen delivery system that will allow a different way of administration, reduce dose and diminish allergen exposure to IgE bound to mast cells or basophils.
Collapse
Affiliation(s)
- Carlos Gamazo
- University of Navarra Dept. Microbiology C/Irunlarrea, 1; 31080 - Pamplona, Spain
| | - Gabriel Gastaminza
- Department Allergy & Clinical Immunology, Clinica Universidad de Navarra Av. Pio XII 36, 31008 – Pamplona, Spain
| | - Marta Ferrer
- Department Allergy & Clinical Immunology, Clinica Universidad de Navarra Av. Pio XII 36, 31008 – Pamplona, Spain
| | - María L Sanz
- Department Allergy & Clinical Immunology, Clinica Universidad de Navarra Av. Pio XII 36, 31008 – Pamplona, Spain
| | - Juan M Irache
- University of Navarra Dept. Pharmacy & Pharmaceutical Technology C/Irunlarrea, 1; 31080 – Pamplona, Spain
| |
Collapse
|
16
|
|
17
|
Naahidi S, Jafari M, Edalat F, Raymond K, Khademhosseini A, Chen P. Biocompatibility of engineered nanoparticles for drug delivery. J Control Release 2012; 166:182-94. [PMID: 23262199 DOI: 10.1016/j.jconrel.2012.12.013] [Citation(s) in RCA: 417] [Impact Index Per Article: 34.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2012] [Revised: 12/06/2012] [Accepted: 12/10/2012] [Indexed: 02/07/2023]
Abstract
The rapid advancement of nanotechnology has raised the possibility of using engineered nanoparticles that interact within biological environments for treatment of diseases. Nanoparticles interacting with cells and the extracellular environment can trigger a sequence of biological effects. These effects largely depend on the dynamic physicochemical characteristics of nanoparticles, which determine the biocompatibility and efficacy of the intended outcomes. Understanding the mechanisms behind these different outcomes will allow prediction of the relationship between nanostructures and their interactions with the biological milieu. At present, almost no standard biocompatibility evaluation criteria have been established, in particular for nanoparticles used in drug delivery systems. Therefore, an appropriate safety guideline of nanoparticles on human health with assessable endpoints is needed. In this review, we discuss the data existing in the literature regarding biocompatibility of nanoparticles for drug delivery applications. We also review the various types of nanoparticles used in drug delivery systems while addressing new challenges and research directions. Presenting the aforementioned information will aid in getting one step closer to formulating compatibility criteria for biological systems under exposure to different nanoparticles.
Collapse
Affiliation(s)
- Sheva Naahidi
- Department of Chemical Engineering, University of Waterloo, 200 University Avenue West, Waterloo, Ontario N2L 3G1, Canada
| | | | | | | | | | | |
Collapse
|
18
|
Martins RDC, Irache JM, Gamazo C. Acellular vaccines for ovine brucellosis: a safer alternative against a worldwide disease. Expert Rev Vaccines 2012; 11:87-95. [PMID: 22149711 DOI: 10.1586/erv.11.172] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Ovine brucellosis is a very contagious zoonotic disease distributed worldwide and constitutes a very important zoosanitary and economic problem. The control of the disease includes animal vaccination and slaughter of infected flocks. However, the commercially available vaccine in most countries is based on the attenuated strain Brucella melitensis Rev 1, which presents important safety drawbacks. This review is focused on the most recent and promising acellular vaccine proposals.
Collapse
Affiliation(s)
- Raquel Da Costa Martins
- Department of Pharmaceutics and Pharmaceutical Technology, University of Navarra, C/Irunlarrea, 1 31008-Pamplona, Spain
| | | | | |
Collapse
|
19
|
Carbohydrate modified ultrafine ceramic nanoparticles for allergen immunotherapy. Int Immunopharmacol 2011; 11:925-31. [DOI: 10.1016/j.intimp.2011.02.004] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2010] [Revised: 01/24/2011] [Accepted: 02/01/2011] [Indexed: 11/23/2022]
|
20
|
|
21
|
Blank F, Gerber P, Rothen-Rutishauser B, Sakulkhu U, Salaklang J, De Peyer K, Gehr P, Nicod LP, Hofmann H, Geiser T, Petri-Fink A, Von Garnier C. Biomedical nanoparticles modulate specific CD4+ T cell stimulation by inhibition of antigen processing in dendritic cells. Nanotoxicology 2011; 5:606-21. [PMID: 21231795 DOI: 10.3109/17435390.2010.541293] [Citation(s) in RCA: 71] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Understanding how nanoparticles may affect immune responses is an essential prerequisite to developing novel clinical applications. To investigate nanoparticle-dependent outcomes on immune responses, dendritic cells (DCs) were treated with model biomedical poly(vinylalcohol)-coated super-paramagnetic iron oxide nanoparticles (PVA-SPIONs). PVA-SPIONs uptake by human monocyte-derived DCs (MDDCs) was analyzed by flow cytometry (FACS) and advanced imaging techniques. Viability, activation, function, and stimulatory capacity of MDDCs were assessed by FACS and an in vitro CD4+ T cell assay. PVA-SPION uptake was dose-dependent, decreased by lipopolysaccharide (LPS)-induced MDDC maturation at higher particle concentrations, and was inhibited by cytochalasin D pre-treatment. PVA-SPIONs did not alter surface marker expression (CD80, CD83, CD86, myeloid/plasmacytoid DC markers) or antigen-uptake, but decreased the capacity of MDDCs to process antigen, stimulate CD4+ T cells, and induce cytokines. The decreased antigen processing and CD4+ T cell stimulation capability of MDDCs following PVA-SPION treatment suggests that MDDCs may revert to a more functionally immature state following particle exposure.
Collapse
Affiliation(s)
- Fabian Blank
- Department of Clinical Research , Division of Pulmonology, Bern University Hospital, Bern, Switzerland
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Zolnik BS, González-Fernández A, Sadrieh N, Dobrovolskaia MA. Nanoparticles and the immune system. Endocrinology 2010; 151:458-65. [PMID: 20016026 PMCID: PMC2817614 DOI: 10.1210/en.2009-1082] [Citation(s) in RCA: 565] [Impact Index Per Article: 40.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/16/2009] [Accepted: 11/19/2009] [Indexed: 11/19/2022]
Abstract
Today nanotechnology is finding growing applications in industry, biology, and medicine. The clear benefits of using nanosized products in various biological and medical applications are often challenged by concerns about the lack of adequate data regarding their toxicity. One area of interest involves the interactions between nanoparticles and the components of the immune system. Nanoparticles can be engineered to either avoid immune system recognition or specifically inhibit or enhance the immune responses. We review herein reported observations on nanoparticle-mediated immunostimulation and immunosuppression, focusing on possible theories regarding how manipulation of particle physicochemical properties can influence their interaction with immune cells to attain desirable immunomodulation and avoid undesirable immunotoxicity.
Collapse
Affiliation(s)
- Banu S Zolnik
- Center for Drug Evaluation and Research, Office of Pharmaceutical Science, Food and Drug Administration, Silver Spring, Maryland 20993, USA
| | | | | | | |
Collapse
|
23
|
Ojer P, Salman H, Da Costa Martins R, Calvo J, López de Cerain A, Gamazo C, Lavandera J, Irache J. Spray-drying of poly(anhydride) nanoparticles for drug/antigen delivery. J Drug Deliv Sci Technol 2010. [DOI: 10.1016/s1773-2247(10)50059-5] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
24
|
Affiliation(s)
- Carlos Gamazo
- Department of Microbiology, Irunlarrea 1, University of Navarra, 31008 Pamplona, Spain.
| | | |
Collapse
|
25
|
Gómez S, Gamazo C, San Roman B, Grau A, Espuelas S, Ferrer M, Sanz ML, Irache JM. A novel nanoparticulate adjuvant for immunotherapy with Lolium perenne. J Immunol Methods 2009; 348:1-8. [DOI: 10.1016/j.jim.2009.06.005] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2009] [Revised: 06/11/2009] [Accepted: 06/15/2009] [Indexed: 11/16/2022]
|